<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05041270</url>
  </required_header>
  <id_info>
    <org_study_id>16-8-2021</org_study_id>
    <nct_id>NCT05041270</nct_id>
  </id_info>
  <brief_title>Epidural Nalbuphine Versus Dexmedetomidine as Adjuvants to Bupivacaine in Lower Limb Surgeries</brief_title>
  <official_title>Epidural Nalbuphine Versus Dexmedetomidine as Adjuvants to Bupivacaine in Lower Limb Surgeries Under Combined Spinal-epidural Anesthesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zagazig University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zagazig University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Combined spinal epidural anesthesia (CSE) with bupivacaine alone is not sufficient to cover&#xD;
      pain sequel during lower limb surgeries.&#xD;
&#xD;
      Previous studies used addition of either Nalbuphine or dexmedetomidine to bupivacaine in&#xD;
      epidural anesthesia giving a good result in pain control.&#xD;
&#xD;
      In this study the investigators will evaluate and compare the addition of either Nalbuphine&#xD;
      or dexmedetomidine to bupivacaine in epidural anesthesia to evaluate the analgesic efficacy&#xD;
      of either drug.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Surgical patients need adequate and effective intraoperative anesthesia and postoperative&#xD;
      analgesia. Neuroaxial block including lower limb spinal and epidural blocks have a long&#xD;
      history of effective anesthesia and lower limb pain relief. Spinal anesthesia is a simple&#xD;
      method requiring small dose of local anesthetic agent to give immediate and effective sensory&#xD;
      and motor block. But one of its major side effects is hypotension and difficulty in&#xD;
      controlling the level of the block [1]. Meanwhile, epidural anesthesia is a safe,&#xD;
      well-practiced, not expensive neuroaxial block technique that provides intraoperative&#xD;
      anesthesia and postoperative analgesia. So, the combined spinal epidural block (CSE) aims to&#xD;
      achieve intense sensory and motor anesthesia and prolong the duration of analgesia&#xD;
      intraoperative extending to postoperative period [2].&#xD;
&#xD;
      Neuroaxial anesthesia and analgesia provide perfect analgesic effect by inhibiting&#xD;
      nociceptive transmission from peripheral to central neuronal system, but this advantage&#xD;
      limited by short half-life of the current local anesthetics. Bupivacaine is a local&#xD;
      anesthetic which belongs to amide group of anesthetic agents that has been widely used for&#xD;
      local infiltration, peripheral nerve block, spinal and epidural anesthesia and despite&#xD;
      relatively long duration of action, still has insufficient time for postoperative analgesia&#xD;
      [3].&#xD;
&#xD;
      Several neuroaxial adjuvants such as (opioids, dexamethasone, magnesium sulphate, midazolam&#xD;
      and dexmedetomidine) can be added to local anesthetics to prolong its duration of anesthesia&#xD;
      and decrease the dose requirement of local anesthetics [4].&#xD;
&#xD;
      Nalbuphine, a derivative of 14-hydroxy morphine is a strong analgesic with mixed kappa&#xD;
      agonist and µ antagonist properties. Its potency is equal to morphine, but exhibits a ceiling&#xD;
      effect on respiratory depression. It has the potential to maintain and enhance µ-opioid based&#xD;
      anesthesia while simultaneously mitigating the µ-opioid side effects [5].&#xD;
&#xD;
      Dexmedetomidine is an imidazole compound. It is a highly selective α-2 adrenergic agonist&#xD;
      with an affinity 8 times more specific when compared to clonidine. It has sedative,&#xD;
      sympatholytic and analgesic effects that blunt cardiovascular responses both intraoperative&#xD;
      and in the perioperative period. Patients remain calm and sedated when undisturbed but arouse&#xD;
      readily with stimulation [6]. Dexmedetomidine causes manageable hypotension and bradycardia,&#xD;
      but the striking feature of this drug is the lack of opioid-related adverse effects like&#xD;
      respiratory depression, pruritis, nausea, and vomiting [7].&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 16, 2021</start_date>
  <completion_date type="Anticipated">January 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The patients will be divided randomly by a computer-generated randomization table into three equal groups</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
    <masking_description>triple blinded (patient, anesthesiologist in the operating room and outcomes assessor)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of epidural analgesia</measure>
    <time_frame>within 24 hour postoperative</time_frame>
    <description>time elapsed from epidural injection of LA until VAS score (≥3)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum level of sensory blockade</measure>
    <time_frame>after 30 min of administering the local anesthetic in the epidural space</time_frame>
    <description>the maximum sensory dermatome level after 30 min of administering the local anesthetic in the epidural space</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of top up doses required</measure>
    <time_frame>within 24 hour postoperative</time_frame>
    <description>When sensory block regress to T12 dermatome Epidural bolus dose will be given</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>assessment of changes in patient's level of sedation</measure>
    <time_frame>Sedation scores will be recorded just before the initiation and 2 hours postoperatively</time_frame>
    <description>assessment of patient's level of sedation using Ramsey sedation score; where 1=patient is anxious and agitated or restless, or both.&#xD;
2= Patient is co-operative, oriented, and tranquil. 3= Patient responds to commands only. 4= Patient exhibits brisk response to light glabellar tap or loud auditory stimulus.&#xD;
5= Patient exhibits a sluggish response to light glabellar tap or loud auditory stimulus.&#xD;
6= Patient exhibits no response.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">23</enrollment>
  <condition>Lower Limb Surgeries</condition>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>patient will be given epidural bolus dose of 12ml (10ml 0.25% bupivacaine + 2ml normal saline), top up dose of 8ml will be given postoperative (6ml 0.25% bupivacaine + 2ml normal saline).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dexmedetomidine group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patient will be given epidural bolus dose of 12ml (10ml 0.25% bupivacaine + 100µg dexmedetomidine in 2ml volume), top up dose of 8ml will be given postoperative (6ml 0.25% bupivacaine + 20µg dexmedetomidine in 2ml volume)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>nalbuphine group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patient will be given epidural bolus dose of 12ml (10ml 0.25% bupivacaine + 10mg nalbuphine in 2ml volume), top up dose of 8ml will be given postoperative (6ml 0.25% bupivacaine + 2mg nalbuphine in 2ml volume)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>normal saline</intervention_name>
    <description>Surgery will be started under spinal anesthesia. When sensory block regress to T12 dermatome Epidural bolus dose will be given epidural bolus dose of 12ml (10ml 0.25% bupivacaine + 2ml normal saline) The onset of sensory blockade injected epiduraly with maximal cephalic spread will be assessed by bilateral pinprick method along the midclavicular line, every 5 min for 30 min and then every 30 min.&#xD;
top up dose of 8ml will be given postoperative (6ml 0.25% bupivacaine + 2ml normal saline).</description>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>Surgery will be started under spinal anesthesia. When sensory block regress to T12 dermatome Epidural bolus dose will be given epidural bolus dose of 12ml (10ml 0.25% bupivacaine + 100µg dexmedetomidine in 2ml volume) The onset of sensory blockade injected epiduraly with maximal cephalic spread will be assessed by bilateral pinprick method along the midclavicular line, every 5 min for 30 min and then every 30 min.&#xD;
top up dose of 8ml will be given postoperative (6ml 0.25% bupivacaine + 20µg dexmedetomidine in 2ml volume).</description>
    <arm_group_label>dexmedetomidine group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nalbuphine</intervention_name>
    <description>Surgery will be started under spinal anesthesia. When sensory block regress to T12 dermatome Epidural bolus dose will be given epidural bolus dose of 12ml (10ml 0.25% bupivacaine + 10mg nalbuphine in 2ml volume) The onset of sensory blockade injected epiduraly with maximal cephalic spread will be assessed by bilateral pinprick method along the midclavicular line, every 5 min for 30 min and then every 30 min.&#xD;
top up dose of 8ml will be given postoperative (6ml 0.25% bupivacaine + 2mg nalbuphine in 2ml volume).</description>
    <arm_group_label>nalbuphine group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patient acceptance.&#xD;
&#xD;
          -  BMI 25-29.9 kg/m2.&#xD;
&#xD;
          -  ASA I and ASA II.&#xD;
&#xD;
          -  Scheduled for elective lower limb orthopedic surgeries under (CSE) block.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient with known allergy to study drugs,&#xD;
&#xD;
          -  Patients suffering from severe chronic diseases (cardiac, renal, hepatic and&#xD;
             neurological or diabetes),&#xD;
&#xD;
          -  Patients with infection at the site of spinal-epidural block,&#xD;
&#xD;
          -  Drug addict patients,&#xD;
&#xD;
          -  Patients on long term steroid therapy,&#xD;
&#xD;
          -  Patients with abnormalities in vertebral spine,&#xD;
&#xD;
          -  Mentally retarded or uncooperative patients,&#xD;
&#xD;
          -  Patients receive anti-coagulant therapy or suspected coagulopathy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Howaida A Kamal, MD</last_name>
    <role>Study Director</role>
    <affiliation>Faculty of medicine, zagazig university, Zagazig, Elsharqya, Egypt, 44519</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rehab A Wahdan, MD</last_name>
    <phone>01003481323</phone>
    <phone_ext>002</phone_ext>
    <email>obz13w@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Manal S Farmawy, MD</last_name>
    <phone>01006330206</phone>
    <phone_ext>002</phone_ext>
    <email>manalsfarmawy@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>faculty of medicine, Zagazig university</name>
      <address>
        <city>Zagazig</city>
        <state>Elsharqya</state>
        <zip>44519</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Howaida A Kamal, MD</last_name>
      <phone>01225096755</phone>
      <phone_ext>002</phone_ext>
      <email>k.howaida@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Shruthi AH, Sudheesh K, Nethra SS, Raghavendra Rao RS, Devika Rani D. THE EFFECT OF A SINGLE DOSE OF MAGNESIUM SULPHATE AS AN ADJUVANT TO EPIDURAL BUPIVACAINE FOR INFRAUMBILICAL SURGERIES: A PROSPECTIVE DOUBLE-BLIND, RANDOMIZED CONTROL TRIAL. Middle East J Anaesthesiol. 2016 Feb;23(4):449-55.</citation>
    <PMID>27382815</PMID>
  </reference>
  <reference>
    <citation>Chatrath V, Attri JP, Bala A, Khetarpal R, Ahuja D, Kaur S. Epidural nalbuphine for postoperative analgesia in orthopedic surgery. Anesth Essays Res. 2015 Sep-Dec;9(3):326-30. doi: 10.4103/0259-1162.158004.</citation>
    <PMID>26712968</PMID>
  </reference>
  <reference>
    <citation>Gupta K, Rastogi B, Gupta PK, Singh I, Bansal M, Tyagi V. Intrathecal nalbuphine versus intrathecal fentanyl as adjuvant to 0.5% hyperbaric bupivacaine for orthopedic surgery of lower limbs under subarachnoid block: A comparative evaluation. Indian J Pain. 2016; 30:90-5.</citation>
  </reference>
  <reference>
    <citation>Chiruvella S, Donthu B, Nallam SR, Salla DB. Postoperative Analgesia with Epidural Dexmedetomidine Compared with Clonidine following Total Abdominal Hysterectomies: A Prospective Double-blind Randomized Trial. Anesth Essays Res. 2018 Jan-Mar;12(1):103-108. doi: 10.4103/aer.AER_207_17.</citation>
    <PMID>29628563</PMID>
  </reference>
  <reference>
    <citation>Soliman AAM, Melika ASM. Epidural bupivacaine and dexmedetomidine versus bupivacaine and opioids for lower vascular surgery. J Med Sci Res. 2018; 1:158-63.</citation>
  </reference>
  <reference>
    <citation>Paul A, Nathroy A, Paul T. A comparative study of dexmedetomidine and fentanyl as an adjuvant to epidural bupivacaine in lower limb surgeries. J Med Sci. 2017; 37:221-6.</citation>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 2, 2021</study_first_submitted>
  <study_first_submitted_qc>September 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2021</study_first_posted>
  <last_update_submitted>September 13, 2021</last_update_submitted>
  <last_update_submitted_qc>September 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zagazig University</investigator_affiliation>
    <investigator_full_name>Rehab Abd-Allah Wahdan</investigator_full_name>
    <investigator_title>lecturer of anesthesia and surgical intensive care</investigator_title>
  </responsible_party>
  <keyword>Epidural Nalbuphine</keyword>
  <keyword>Epidural Dexmedetomidine</keyword>
  <keyword>combined spinal-epidural anesthesia</keyword>
  <keyword>lower limb surgeries</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Nalbuphine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>planned after the completion of the study and publication</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>planned after the completion of the study and publication</ipd_time_frame>
    <ipd_access_criteria>principal investigator</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

